E. Aamdal

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

E. Hovig, G. Bounova, T. Clancy, 2022, Journal of translational medicine.

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

E. Hovig, S. Aamdal, T. Guren, 2022, Journal for ImmunoTherapy of Cancer.

Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment

S. Kaasa, O. Straume, E. Skovlund, 2022, ESMO open.

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

E. Hovig, G. Bounova, T. Clancy, 2022, Journal of translational medicine.

Ipilimumab in a real‐world population: A prospective Phase IV trial with long‐term follow‐up

S. Kaasa, H. Russnes, S. Aamdal, 2021, International journal of cancer.

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

E. Hovig, D. Vodák, S. Nakken, 2021, Frontiers in Immunology.

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

S. Aamdal, K. Taskén, G. Maelandsmo, 2019, Clinical and experimental immunology.

Second-line Oral Vinorelbine Following First-Line Platinum and Pemetrexed in Malignant Pleural Mesothelioma

J. Sørensen, S. Langer, E. Urbanska, 2012 .